

**Calendar No. 340**119<sup>TH</sup> CONGRESS  
2<sup>D</sup> SESSION**S. 233****[Report No. 119-111]**

To amend the Office of National Drug Control Policy Reauthorization Act of 2006 to modify the authority of the Office of National Drug Control Policy with respect to the World Anti-Doping Agency, and for other purposes.

---

**IN THE SENATE OF THE UNITED STATES**

JANUARY 23, 2025

Mrs. BLACKBURN (for herself, Mr. VAN HOLLEN, Mrs. CAPITO, Mr. BLUMENTHAL, Mr. WICKER, Ms. BLUNT ROCHESTER, and Mr. LUJÁN) introduced the following bill; which was read twice and referred to the Committee on Commerce, Science, and Transportation

FEBRUARY 23, 2026

Reported by Mr. CRUZ, with an amendment

[Strike out all after the enacting clause and insert the part printed in *italic*]

---

**A BILL**

To amend the Office of National Drug Control Policy Reauthorization Act of 2006 to modify the authority of the Office of National Drug Control Policy with respect to the World Anti-Doping Agency, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Restoring Confidence  
3 in the World Anti-Doping Agency Act of 2025”.

4 **SEC. 2. AUTHORITY OF NATIONAL DRUG CONTROL POLICY**  
5 **WITH RESPECT TO THE WORLD ANTI-DOPING**  
6 **AGENCY.**

7 Section 701 of the Office of National Drug Control  
8 Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is  
9 amended—

10 (1) in subsection (a)—

11 (A) by amending paragraph (1) to read as  
12 follows:

13 “(1) UNITED STATES OLYMPIC AND  
14 PARALYMPIC COMMITTEE.—The term ‘United States  
15 Olympic and Paralympic Committee’ means the or-  
16 ganization established by chapter 2205 of title 36,  
17 United States Code.”;

18 (B) in paragraph (3), by striking “(36  
19 U.S.C. 22501(b)(1))” and inserting “(36  
20 U.S.C. 220501(b)(1))”;

21 (C) by redesignating paragraphs (1) and  
22 (3) as paragraphs (4) and (1), respectively, and  
23 moving the paragraphs so as to appear in nu-  
24 meric order; and

25 (D) by inserting after paragraph (2) the  
26 following:

1           “(3) INDEPENDENT ATHLETE.—The term  
2           ‘independent athlete’ means an Olympic or  
3           Paralympic athlete who does not serve, in any capac-  
4           ity—

5                   “(A) on the International Olympic Com-  
6                   mittee;

7                   “(B) on the International Paralympic  
8                   Committee;

9                   “(C) at an international sports federation  
10                  recognized by the International Olympic Com-  
11                  mittee or the International Paralympic Com-  
12                  mittee;

13                  “(D) on the United States Olympic and  
14                  Paralympic Committee; or

15                  “(E) at the World Anti-Doping Agency.”;  
16                  (2) in subsection (b)—

17                   (A) by striking “United States Olympic  
18                   Committee” each place it appears and inserting  
19                   “United States Olympic and Paralympic Com-  
20                   mittee”;

21                   (B) in paragraph (5), by striking the pe-  
22                   riod at the end and inserting “; and”;

23                   (C) by adding at the end the following:

1           “(6) carry out responsibilities with respect to  
2           the World Anti-Doping Agency, as described in sub-  
3           section (d).”;

4           (3) by adding at the end the following:

5           “(d) AUTHORITY WITH RESPECT TO THE WORLD  
6           ANTI-DOPING AGENCY.—

7           “(1) IN GENERAL.—The Office of National  
8           Drug Control Policy, in consultation with the United  
9           States Anti-Doping Agency, the United States Olym-  
10          pic and Paralympic Committee, and the Team USA  
11          Athletes’ Commission, shall—

12           “(A) use all available tools to ensure  
13          that—

14           “(i) the World Anti-Doping Agency  
15           has a credible and independent governance  
16           model that provides for fair representation  
17           of the United States;

18           “(ii) the World Anti-Doping Agency  
19           fully implements all governance reforms,  
20           including a proper conflict-of-interest pol-  
21           icy for all members of the Executive Com-  
22           mittee, the Foundation Board, and all rel-  
23           evant expert advisory groups, standing  
24           committees, permanent special committees,

1 and working groups of the World Anti-  
2 Doping Agency; and

3 “(iii) independent athletes from the  
4 United States and other democratic coun-  
5 tries; or representatives of such athletes;  
6 have decision-making roles on the Execu-  
7 tive Committee and the Foundation Board;  
8 and in all relevant expert advisory groups;  
9 standing committees; permanent special  
10 committees; and working groups; of the  
11 World Anti-Doping Agency;

12 “(B) demonstrate leadership within the  
13 global community;

14 “(C) have strict standards that work to-  
15 ward countering doping in every form, including  
16 by countering systemic fraud through doping  
17 involving—

18 “(i) governmental law enforcement,  
19 intelligence; or anti-doping institutions;

20 “(ii) sporting organizations; or

21 “(iii) athlete support personnel; and

22 “(D) work collaboratively with democratic  
23 countries.

24 “(2) DETERMINATION.—

1           “(A) IN GENERAL.—Not later than 90  
2 days after the date of the enactment of this  
3 subsection, the Office of National Drug Control  
4 Policy, in consultation with the United States  
5 Anti-Doping Agency, the United States Olympic  
6 and Paralympic Committee, and the Team USA  
7 Athletes’ Commission, shall make a determina-  
8 tion as to whether the World Anti-Doping  
9 Agency—

10           “(i) has a credible and independent  
11 governance model that provides for fair  
12 representation of the United States;

13           “(ii) fully implements all governance  
14 reforms, including a proper conflict-of-in-  
15 terest policy described in paragraph  
16 (1)(A)(ii); and

17           “(iii) allows independent athletes from  
18 the United States and other democratic  
19 countries, or representatives of such ath-  
20 letes, to have decision-making roles on the  
21 Executive Committee and the Foundation  
22 Board, and in all relevant expert advisory  
23 groups, standing committees, permanent  
24 special committees, and working groups, of  
25 the World Anti-Doping Agency.

1           “(B) ACCOUNTABILITY.—In the case of a  
2           determination under subparagraph (A) that the  
3           World Anti-Doping Agency does not have such  
4           a governance model, has not fully implemented  
5           such governance reforms, or has not allowed de-  
6           cision-making roles described in clause (iii) of  
7           that subparagraph, the Office of National Drug  
8           Control Policy, in consultation with the United  
9           States Anti-Doping Agency, the United States  
10          Olympic and Paralympic Committee, and the  
11          Team USA Athletes’ Commission, shall—

12                   “(i) use all available tools to ensure  
13                   that the United States has fair representa-  
14                   tion in the World Anti-Doping Agency, in-  
15                   cluding—

16                           “(I) on the Executive Committee;

17                           “(II) on the Foundation Board;

18                           and

19                           “(III) in all relevant expert advi-  
20                           sory groups, standing committees,  
21                           permanent special committees, and  
22                           working groups of the World Anti-  
23                           Doping Agency; and

24                           “(ii) not later than 180 days after the  
25                           date on which the determination under

1           subparagraph (A) is made, issue a report  
2           that describes the barriers to participation  
3           and fair representation of the United  
4           States on the Executive Committee, the  
5           Foundation Board, and all relevant expert  
6           advisory groups, standing committees, per-  
7           manent special committees, and working  
8           groups of the World Anti-Doping Agency.

9           “(3) VOLUNTARY NONPAYMENT OF DUES.—

10           “(A) IN GENERAL.—In the case of a deter-  
11           mination under paragraph (2)(A) that the  
12           World Anti-Doping Agency does not have a gov-  
13           ernance model that provides for fair representa-  
14           tion of the United States, has not fully imple-  
15           mented governance reforms, or has not allowed  
16           decision-making roles described in clause (iii) of  
17           that subparagraph, the Office of National Drug  
18           Control Policy, in consultation with the appro-  
19           priate committees of Congress, may voluntarily  
20           withhold up to the full amount of membership  
21           dues to the World Anti-Doping Agency.

22           “(B) APPROPRIATE COMMITTEES OF CON-  
23           GRESS DEFINED.—In this paragraph, the term  
24           ‘appropriate committees of Congress’ means—

1           “(i) the Subcommittee on Consumer  
2           Protection, Product Safety, and Data Se-  
3           curity of the Committee on Commerce,  
4           Science, and Transportation of the Senate  
5           (or a successor subcommittee);

6           “(ii) the Subcommittee on Financial  
7           Services and General Government of the  
8           Committee on Appropriations of the Sen-  
9           ate (or a successor subcommittee);

10          “(iii) the Subcommittee on Oversight  
11          and Investigations of the Committee on  
12          Energy and Commerce of the House of  
13          Representatives (or a successor sub-  
14          committee); and

15          “(iv) the Subcommittee on Financial  
16          Services and General Government of the  
17          Committee on Appropriations of the House  
18          of Representatives (or a successor sub-  
19          committee).

20          “(4) SPENDING PLAN.—Not later than 30 days  
21          before the Office of National Drug Control Policy  
22          obligates funds to the World Anti-Doping Agency,  
23          the Office of National Drug Control Policy shall sub-  
24          mit to the Committee on Appropriations of the Sen-  
25          ate and the Committee on Appropriations of the

1 House of Representatives a spending plan and explain-  
 2 nation of proposed uses of such funds.”.

3 **SECTION 1. SHORT TITLE.**

4 *This Act may be cited as the “Restoring Confidence*  
 5 *in the World Anti-Doping Agency Act of 2025”.*

6 **SEC. 2. AUTHORITY OF NATIONAL DRUG CONTROL POLICY**

7 **WITH RESPECT TO THE WORLD ANTI-DOPING**  
 8 **AGENCY.**

9 *Section 701 of the Office of National Drug Control Pol-*  
 10 *icy Reauthorization Act of 2006 (21 U.S.C. 2001) is amend-*  
 11 *ed—*

12 *(1) by striking subsection (a) and inserting the*  
 13 *following:*

14 *“(a) DEFINITIONS.—In this subchapter:*

15 *“(1) AMATEUR ATHLETE.—The term ‘amateur*  
 16 *athlete’ has the meaning given that term in section*  
 17 *220501(b)(1) of title 36, United States Code.*

18 *“(2) AMATEUR ATHLETIC COMPETITION.—The*  
 19 *term ‘amateur athletic competition’ has the meaning*  
 20 *given that term in section 220501(b)(2) of title 36,*  
 21 *United States Code.*

22 *“(3) INDEPENDENT ATHLETE.—The term ‘inde-*  
 23 *pendent athlete’ means a current or former amateur*  
 24 *athlete who does not serve, in any capacity—*

1           “(A) on the International Olympic Com-  
2           mittee;

3           “(B) on the International Paralympic Com-  
4           mittee;

5           “(C) at an international sports federation  
6           recognized by the International Olympic Com-  
7           mittee or the International Paralympic Com-  
8           mittee;

9           “(D) on the United States Olympic and  
10          Paralympic Committee;

11          “(E) at a national governing body (as de-  
12          fined in section 220501(b)(9) of title 36, United  
13          States Code); or

14          “(F) at the World Anti-Doping Agency.

15          “(4) UNITED STATES OLYMPIC AND PARALYMPIC  
16          COMMITTEE.—The term ‘United States Olympic and  
17          Paralympic Committee’ means the organization es-  
18          tablished by chapter 2205 of title 36, United States  
19          Code.”;

20          (2) in subsection (b), by striking “United States  
21          Olympic Committee” each place it appears and in-  
22          serting “United States Olympic and Paralympic  
23          Committee”; and

24          (3) by adding at the end the following:

1       “(d) *AUTHORITY WITH RESPECT TO THE WORLD*  
2 *ANTI-DOPING AGENCY.*—

3               “(1) *ANNUAL DETERMINATION.*—*Not later than*  
4 *180 days after the date of the enactment of this sub-*  
5 *section, and annually thereafter, the Office of Na-*  
6 *tional Drug Control Policy, in consultation with the*  
7 *United States Anti-Doping Agency, the United States*  
8 *Olympic and Paralympic Committee, and the Ath-*  
9 *letes’ Advisory Council (established and maintained*  
10 *under section 220504(b)(2)(A) of title 36, United*  
11 *States Code) shall make a determination as to wheth-*  
12 *er the World Anti-Doping Agency—*

13               “(A) *has a credible and independent govern-*  
14 *ance model that provides for fair representation*  
15 *of the United States;*

16               “(B) *fully implements or has implemented*  
17 *governance reforms to ensure independent gov-*  
18 *ernance; and*

19               “(C) *has fair processes and procedures to se-*  
20 *lect independent athletes, including athletes from*  
21 *the United States and other democratic coun-*  
22 *tries, or representatives of such athletes, for deci-*  
23 *sion-making roles on the Executive Committee*  
24 *and the Foundation Board, and in all relevant*  
25 *expert advisory groups, standing committees,*

1           *permanent special committees, and working*  
2           *groups of the World Anti-Doping Agency.*

3           “(2) *ACCOUNTABILITY.*—*In the case of a deter-*  
4           *mination under paragraph (1) that the World Anti-*  
5           *Doping Agency has not met the criteria set forth in*  
6           *subparagraphs (A), (B), or (C) of that paragraph, the*  
7           *Office of National Drug Control Policy, in consulta-*  
8           *tion with the United States Anti-Doping Agency, the*  
9           *United States Olympic and Paralympic Committee,*  
10          *and the Athletes’ Advisory Council (established and*  
11          *maintained under section 220504(b)(2)(A) of title 36,*  
12          *United States Code), shall use all available tools and*  
13          *best efforts to bring the World Anti-Doping Agency*  
14          *into compliance with the criteria set forth in that*  
15          *paragraph.*

16          “(3) *REPORT.*—*In the case of a determination*  
17          *under paragraph (1) that the World Anti-Doping*  
18          *Agency has not met the criteria set forth in subpara-*  
19          *graphs (A), (B), or (C) of that paragraph, not later*  
20          *than 180 days after the date on which that deter-*  
21          *mination is made, the Office of National Drug Con-*  
22          *trol Policy, in consultation with the United States*  
23          *Anti-Doping Agency, the United States Olympic and*  
24          *Paralympic Committee, and the Athletes’ Advisory*  
25          *Council (established and maintained under section*

1       220504(b)(2)(A) of title 36, United States Code) shall  
2       submit to the appropriate committees of Congress a  
3       report that describes the barriers to participation and  
4       fair representation of the United States on the Execu-  
5       tive Committee, the Foundation Board, and all rel-  
6       evant expert advisory groups, standing committees,  
7       permanent special committees, and working groups of  
8       the World Anti-Doping Agency.

9               “(4) VOLUNTARY NONPAYMENT OF DUES.—

10              “(A) IN GENERAL.—In the case of a deter-  
11              mination under paragraph (1) that the World  
12              Anti-Doping Agency has not met the criteria set  
13              forth in subparagraphs (A), (B), or (C) of that  
14              paragraph, the Office of National Drug Control  
15              Policy, in consultation with the appropriate  
16              committees of Congress, may voluntarily with-  
17              hold up to the full amount of any funds made  
18              available for the payment of the United States  
19              membership dues to the World Anti-Doping  
20              Agency.

21              “(B) RETURN OF FUNDS AFTER NON-  
22              COMPLIANCE.—Unless otherwise specified by law,  
23              any funds made available for the payment of the  
24              United States membership dues to the World  
25              Anti-Doping Agency that have been voluntarily

1           *withheld pursuant to subparagraph (A) and have*  
2           *not been obligated prior to the end of an applica-*  
3           *ble fiscal year shall be returned to the general*  
4           *fund of the Treasury.*

5           “(5) *SPENDING PLAN.*—*Not later than 30 days*  
6           *before the Office of National Drug Control Policy obli-*  
7           *gates funds to the World Anti-Doping Agency, the Of-*  
8           *fice of National Drug Control Policy shall submit to*  
9           *the appropriate committees of Congress a spending*  
10          *plan and explanation of proposed uses of such funds.*

11          “(6) *APPROPRIATE COMMITTEES OF CONGRESS*  
12          *DEFINED.*—*In this subsection, the term ‘appropriate*  
13          *committees of Congress’ means—*

14                 “(A) *the Committee on Commerce, Science,*  
15                 *and Transportation of the Senate;*

16                 “(B) *the Committee on Appropriations of*  
17                 *the Senate;*

18                 “(C) *the Committee on Energy and Com-*  
19                 *merce of the House of Representatives; and*

20                 “(D) *the Committee on Appropriations of*  
21                 *the House of Representatives.”.*

**Calendar No. 340**

119<sup>TH</sup> CONGRESS  
2<sup>D</sup> SESSION

**S. 2333**

[Report No. 119-1111]

---

---

**A BILL**

To amend the Office of National Drug Control Policy Reauthorization Act of 2006 to modify the authority of the Office of National Drug Control Policy with respect to the World Anti-Doping Agency, and for other purposes.

---

---

FEBRUARY 23, 2026

Reported with an amendment